论文部分内容阅读
目的:制备半乳糖-羧化壳聚糖-十四酸纳米粒(galactose carboxyl chitosan myristic acid nanoparticles,GCCMA),观察GCCMA纳米粒在肝癌细胞中的靶向性.方法:本实验组采用自组装法制备GCCMA纳米粒,优化制备条件,并经过本实验组鉴定稳定性及生物相容性,纳米粒经荧光标记后分别取不同浓度转染肝癌细胞及HT22海马神经细胞,对照组、HT22海马神经细胞组和肝癌细胞组,以及对照组、肝癌细胞-low组、肝癌细胞-mid组和肝癌细胞-high组(置入的GCCMA纳米粒浓度由低到高),分别于1、2和4h时间点测定在细胞摄取纳米粒情况.结果:相同浓度的GCCMA纳米粒,Huh7肝癌细胞摄取量显著高于HT22海马神经细胞,肝癌细胞摄取量在特定区间有剂量依赖性,较高浓度时摄取量较大,在1、2和4h时间点所测定的结果显示,4h时肝癌细胞的摄取量最大.结论:GCCMA纳米粒有肝靶向性,为肝脏肿瘤的靶向性基因治疗或化疗药物提供很好的药物载体及给药途径.
Objective: To prepare galactose-carboxyl chitosan-myristic acid nanoparticles (GCCMA) and observe the targeting of GCCMA nanoparticles in hepatocellular carcinoma cells.Methods: The self-assembly method GCCMA nanoparticles were prepared and the preparation conditions were optimized. The stability and biocompatibility of GCCMA nanoparticles were identified. The nanoparticles were transfected into hepatocellular carcinoma cells and HT22 hippocampal neurons, control group, HT22 hippocampal neurons Group and the hepatocellular carcinoma cell group, and the control group, the hepatoma-low group, the hepatoma -mid group, and the hepatoma -high group (low to high concentrations of GCCMA nanoparticles incorporated) at the time points of 1, 2 and 4 h The uptake of GCCMA nanoparticles and Huh7 hepatoma cells at the same concentration was significantly higher than that of HT22 hippocampal neurons, and the uptake of hepatocellular carcinoma cells was dose-dependent in a certain range and the uptake was higher at higher concentrations , At 1, 2 and 4 h time points measured results showed that 4h liver cell uptake of the largest.Conclusion: GCCMA nanoparticles have liver-targeting, liver cancer targeted gene therapy or chemotherapy drugs Provide a good drug carrier and route of administration.